Literature DB >> 13679855

Development of CD30+ lymphoproliferative disease in mice lacking interferon regulatory factor-1.

Donna D Eason1, Cynthia LeBron, Domenico Coppola, Lynn C Moscinski, Sandra Livingston, E Truitt Sutton, George Blanck.   

Abstract

Human lymphomas continue to represent a major challenge in oncology, and in particular occur at very high frequencies in AIDS patients. We report here the development of a CD30+ lymphoproliferative disease in mice lacking the proapoptotic transcription factor, interferon regulatory factor-1. These mice most closely represent a model of human anaplastic large-cell lymphoma (ALCL). This mouse model of lymphoma will likely be useful in understanding the development of ALCL and in understanding the development of other closely related CD30+ forms of lymphoma, such as CD30+ Hodgkin's disease and CD30+ cutaneous T-cell lymphoma. This mouse model will also be useful in testing therapies for different forms of CD30+ lymphoma, in particular anti-CD30-based therapies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679855     DOI: 10.1038/sj.onc.1206563

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  2 in total

1.  Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.

Authors:  Nicole Clarke; Ana M Jimenez-Lara; Emilie Voltz; Hinrich Gronemeyer
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

2.  Genome-wide Identification of IRF1 Binding Sites Reveals Extensive Occupancy at Cell Death Associated Genes.

Authors:  Alessandro Rettino; Nicole M Clarke
Journal:  J Carcinog Mutagen       Date:  2013
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.